renal cell carcinoma market insights, renal cell carcinoma market share, renal cell carcinoma market growth, renal cell carcinoma market trends, renal cell carcinoma market research, renal cell carcinoma market data
How large is the renal cell carcinoma market, and what is its growth trajectory?
The renal cell carcinoma market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rise in prevalence of kidney cancer, increase in geriatric population, growth in adoption of targeted therapies, heightened awareness of cancer screening, improved healthcare infrastructure, and rise in investments in oncology research and development.
The renal cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, growing awareness about early cancer detection, rising healthcare investments in oncology, improved access to healthcare, and expanding clinical trials and research on novel therapies. Major trends in the forecast period include integration of AI for precision diagnostics, development of targeted therapies, innovations in immunotherapy, advancements in biomarker identification, adoption of minimally invasive surgical techniques, and advancements in imaging technologies.
Get Your Free Sample of The Global Renal Cell Carcinoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20944&type=smp
What are the key forces behind the renal cell carcinoma market’s growth in recent years?
The rise in the geriatric population is expected to drive the growth of the renal cell carcinoma market going forward. The geriatric population consists of elderly individuals, usually aged 65 and above, who may have particular healthcare and social requirements. The growing elderly population is driven by healthcare improvements, better nutrition, and longer life spans. Renal cell carcinoma (RCC) is increasingly prevalent in the geriatric population, highlighting the need for tailored screening and treatment strategies for older adults. For instance, in January 2024, according to a report published by the Population Reference Bureau, a US-based non-profit organization responsible for collecting stats for research and academic purposes, the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the rise in the geriatric population is driving the growth of the renal cell carcinoma market.
What are the major segments of the renal cell carcinoma market?
The renal cell carcinoma market covered in this report is segmented –
1) By Type: Clear Cell Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma (RCC)
2) By Diagnosis: Urine Tests, Computed Tomography (CT) Scan, Nephrectomy, Blood Tests, Ultrasound, Biopsy
3) By Treatment: Medication, Ablation, Targeted Therapy, Chemotherapy, Surgery, Other Treatments
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Clear Cell Renal Cell Carcinoma (RCC): Sporadic Clear Cell RCC, Hereditary Clear Cell RCC
2) By Papillary Renal Cell Carcinoma (RCC): Type 1 Papillary RCC, Type 2 Papillary RCC
3) By Chromophobe Renal Cell Carcinoma (RCC): Classic Chromophobe RCC, Hybrid Chromophobe RCC
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/renal-cell-carcinoma-global-market-report
Which companies dominate the renal cell carcinoma market?
Major companies operating in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics
How will emerging trends drive the renal cell carcinoma market throughout the forecast period?
Major companies operating in the renal cell carcinoma market are focusing on developing technologically advanced products, such as integrating artificial intelligence (AI)-powered solutions designed for the analysis of kidney biopsies to enhance diagnostic accuracy, streamline procedures, and improve patient outcomes. An artificial intelligence (AI)–powered solution for analyzing kidney biopsies is a technology-driven tool that leverages machine learning algorithms and computer vision to assist pathologists and nephrologists in evaluating kidney tissue samples. These solutions aim to enhance accuracy, efficiency, and consistency in diagnosing kidney diseases and assessing kidney health. For instance, in March 2024, Aiosyn, a Netherlands-based software company, launched the NephroPath platform, an advanced AI-powered solution designed to analyze kidney biopsies. The NephroPath platform uses computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and precisely counting and assessing glomeruli. This AI-driven analysis ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, overcoming the drawbacks of traditional scoring methods and observer subjectivity.
What are the key regional dynamics of the renal cell carcinoma market, and which region leads in market share?
North America was the largest region in the renal cell carcinoma market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renal cell carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Renal Cell Carcinoma Market Report 2025 Offer?
The renal cell carcinoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Renal cell carcinoma (RCC) is a form of kidney cancer originating in the renal tubules, the structures in the kidneys responsible for filtering waste and producing urine. This cancer begins when cells in the kidney become abnormal and grow uncontrollably, forming a tumor. This can disrupt the kidney’s function, including its ability to filter waste from the blood and produce urine.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20944
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
